Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CXCL10/IP-10 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6502H10024N1736O2026S48 |
| Molar mass | 146468.72 g·mol−1 |
This drug was developed by Bristol-Myers Squibb and Medarex.[4]
References
edit- ^ a b Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. (April 2016). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's & Colitis. 10 (4): 418–28. doi:10.1093/ecco-jcc/jjv224. PMC 4946756. PMID 26721935.418-28&rft.date=2016-04&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946756#id-name=PMC&rft_id=info:pmid/26721935&rft_id=info:doi/10.1093/ecco-jcc/jjv224&rft.aulast=Sandborn&rft.aufirst=WJ&rft.au=Colombel, JF&rft.au=Ghosh, S&rft.au=Sands, BE&rft.au=Dryden, G&rft.au=Hébuterne, X&rft.au=Leong, RW&rft.au=Bressler, B&rft.au=Ullman, T&rft.au=Lakatos, PL&rft.au=Reinisch, W&rft.au=Xu, LA&rft.au=Luo, A&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946756&rfr_id=info:sid/en.wikipedia.org:Eldelumab" class="Z3988">
- ^ a b "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
- ^ "Eldelumab". AdisInsight. Springer Nature Switzerland AG.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |